Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bristol Myers...

    Bristol Myers Opdivo-Yervoy combo misses main goal in late-stage skin cancer trial

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-24T09:15:37+05:30  |  Updated On 24 Nov 2019 9:15 AM IST
    Bristol Myers Opdivo-Yervoy combo misses main goal in late-stage skin cancer trial

    The trial was testing Bristol-Myers' drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma.


    New Delhi: Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed the main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.


    The company said the trial will continue unchanged as per the recommendation of a data monitoring committee.


    The trial was testing Bristol-Myers' drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma.


    Read Also: Bristol Myers Squibb gets FTC okay for acquiring Celgene


    The combination failed to show a statistically significant benefit in patients whose tumours had 1% or lower levels of the PD-L1 protein being targeted, the company said.


    The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell.


    Read Also: Bristol-Myers Opdivo, Yervoy combination gets USFDA priority review for advanced HCC

    advanced melanomaBristol-MyersBristol-Myers Squibbcancercancer drugClinical Triallast stage trialoncologyOpdivopharmapharma companypharma newsskin cancerYervoy
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok